Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TSG-01 for chronic heart failure with reduced ejection fraction and qi deficiency-blood stasis syndrome
CTR20250952Phase 3Active
- Sponsor
- Shanghai Huiyu Biopharmaceutical Technology
- Start
- Jul 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing TSG-01 with TSG-01 placebo (2 arms). Primary endpoints: Change in left ventricular ejection fraction and Change in 6-minute walk distance. Started Jul 2025; status: active.
02
Drugs
TSG-01
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on CTR20250952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250952.